Literature DB >> 18066567

Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.

Arzu Saglam1, Gurkan Bozdag, Gamze Mocan Kuzey, Turkan Kuçukali, Ali Ayhan.   

Abstract

OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
MATERIALS AND METHODS: A case report from a tertiary health center.
RESULTS: A woman presenting with postmenopausal bleeding and abdominal distantion was assessed by endometrial biopsy and explorative surgery. The frozen section of the mass on the right adnex revealed malign mucinous carcinoma of the ovary. As usual, optimal debulking was performed as initial surgical staging procedure of ovarian cancer. The microscopic examination of the right ovary revealed a typical mucinous cystadenocarcinoma. Furthermore, the focal endometrial irregularity at the left uterine cornus turned out to be a well differentiated endometrial carcinoma of the endometrioid type with <1/3 myometrial invasion. The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery. Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern. DISCUSSION: When compared with patients having metastatic lesions, most synchronous female malignancies are accompanied with early stage and low-grade with a more favorable prognosis. However, there is paucity of data for the exact criterion to distinguish primary tumors from metastatic lesions. In such cases, the validity of immunohistochemical and cloning studies are not clear.

Entities:  

Mesh:

Year:  2008        PMID: 18066567     DOI: 10.1007/s00404-007-0520-4

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  Synchronous occurrence of endometrial stromal nodule with papillary serous carcinoma of ovary: report of a case and brief review of literature.

Authors:  Sumit Mitra; Uttara Chatterjee; Suchandra Ray; Debasis Mukhopadhyay; Sanghamitra Mukhopadhyay
Journal:  J Obstet Gynaecol India       Date:  2013-08-30

2.  Triple Synchronous Malignancies in Genital Tract; Primary Endometrial, Ovarian and Fallopian Tube Carcinoma: A Case Report.

Authors:  Ozgur Kan; Aysegul Alkilic; Batuhan Turgay; Ali Gemici; Cem Somer Atabekoglu
Journal:  J Clin Diagn Res       Date:  2017-01-01

3.  Triple synchronous tumour of female genital tract: cervical squamous cell carcinoma, right ovarian dermoid cyst and left ovarian benign Brenner tumour.

Authors:  Amit Kumar Adhya; Ranjan Mohanty
Journal:  BMJ Case Rep       Date:  2019-07-21

4.  Diffusion-weighted magnetic resonance imaging to detect synchronous uterine endometrial and endocervical adenocarcinoma.

Authors:  Jesus Paul Carvalho; Publio Viana; Cristina Anton; Giovanni Favero; Alexandre Silva E Silva; Edmund Chada Baracat; Filomena Marino Carvalho
Journal:  Rare Tumors       Date:  2012-03-20

5.  Triple Synchronous Primary Neoplasms of the Cervix, Endometrium, and Ovary: A Rare Case Report and Summary of All the English PubMed-Indexed Literature.

Authors:  Ahmed Abu-Zaid; Mohannad Alsabban; Mohammed Abuzaid; Osama Alomar; Hany Salem; Ismail A Al-Badawi
Journal:  Case Rep Obstet Gynecol       Date:  2017-08-23

6.  Serous adenocarcinoma of the fallopian tube, associated with verrucous carcinoma of the uterine cervix: a case report of synchronic rare gynecological tumors.

Authors:  David Cantu de Leon; Delia Perez Montiel; Adan Tabarez; Rocio Mendez Martinez; Lucely Cetina
Journal:  World J Surg Oncol       Date:  2009-02-17       Impact factor: 2.754

7.  Synchronous quadruple primary malignancies of the cervix, endometrium, ovary, and stomach in a single patient: A case report and review of literature.

Authors:  Dan-Dan Wang; Qing Yang
Journal:  World J Clin Cases       Date:  2019-10-26       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.